SRI International today announced a research agreement with Ionis Pharmaceuticals, combining SRI’s proprietary FOX Three Molecular Guidance cellular targeting system (MGS) with Ionis’ proprietary antisense drug-discovery platform.
SRI’s FOX Three MGS technology is designed to overcome cellular barriers that prevent intracellular delivery of large-molecule biotherapeutics. The platform uses proprietary technology that enables the delivery of macromolecular payloads to select cells and subcellular locations in those cells.
SRI has demonstrated that the FOX Three MGS technology can deliver more than a dozen different types of payloads – from functional enzymes, antibodies and DNA, to liposomes and nanoparticles – to targeted, intracellular molecular-target locations previously considered undruggable.
“Fox Three creates the potential to greatly expand the use of biotherapeutics,” said Nathan Collins, Ph.D., vice president of SRI Biosciences, a division of SRI International. “Ionis is an ideal partner to further explore the utility of this technology in the intracellular delivery of nucleic acid-based drugs. We look forward to seeing what we can accomplish through thoughtful combination of our novel technologies.”
About SRI Biosciences
SRI Biosciences, a division of SRI International, integrates basic biomedical research with drug and diagnostics discovery and preclinical and clinical development. SRI International, a research center headquartered in Menlo Park, California, creates world-changing solutions to make people safer, healthier, and more productive.
